with resistant disease reached CR. Incidence of OS and DFS at 3 years was 78 and 81%. DFS was similar for In the present paper, we evaluate tolerability, outcome patients transplanted with early or late relapse (95 and and prognostic factors in patients with poor prognosis 93%). With multivariate analysis, the only independent non-Hodgkin's lymphoma (NHL) and Hodgkin's disvariable for OS was CR after transplant. In conclusion, ease (HD) when uniformly treated with BCNU, etopothe present results demonstrate the efficacy and low toxside, cytarabine and melphalan (BEAM) and autologous icity of the BEAM regimen in high-risk lymphoma stem cell transplant (ASCT). One hundred and fortypatients with sensitive disease. Other strategies should eight patients with NHL (n = 112) or HD (n = 36) be investigated for patients with refractory lymphoma. received BEAM followed by infusion of bone marrow Keywords: non-Hodgkin's lymphoma; Hodgkin's dis- well as in those with Hodgkin's disease, a high rate of compatients were transplanted in 1st CR due to the presence plete remission (CR) and long-term survival are achieved of у2 adverse prognostic features at diagnosis or to a with conventional chemotherapy. 1-5 However, the progslow CR. Of the HD patients at transplant 17 had active nosis is poor for those who fail to achieve CR or who disease, 16 were in у2 CR and three in 1st CR. The relapse after chemotherapy. Response to standard salvage overall percentage of toxic deaths was 5.4%, while in therapy in these latter patients ranges between 20 and 60% the group of patients transplanted with PBSC it was and durable remissions are rarely observed. 6,7 Moreover, in only 1.3%. NHL patients: 78% were in CR following NHL patients with two or more adverse prognostic factors ASCT, including 25 out of 45 patients (56%) who were according to the international index, conventional treatment transplanted with active disease. Only two of the 11 offers very poor results (37 and 21% disease-free survival patients transplanted with resistant disease achieved after 5 years). 8 Two recent reports have shown the benefits CR. Incidence of overall survival (OS) and disease-free of bone marrow transplantation (BMT) compared to survival (DFS) at 3 years was 65 and 75%, respectively. chemotherapy both in patients in first relapse 9 and in those As far as histology was concerned, OS was significantly in first CR with poor prognostic factors. 10 In spite of probetter for patients with LGL in comparison with IGL longed initial reponse and long survival, indolent lym-(88 vs 56%) (P = 0.002). DFS was significantly higher phomas are ultimately as lethal as other NHL and confor patients transplanted in first CR or first partial sidered incurable with conventional chemotherapy. 11 Some remission (PR) than it was for those transplanted in a recent reports 12,13 have validated the international prognoslater CR or PR (86 vs 53%) (P = 0.02). Multivariate tic index (IPI) for patients with follicular lymphoma and analysis for OS showed that histology, bulky disease, suggest that prognostic factors are similar to those poor performance status at transplant and achievement described for intermediate-and high-grade NHL. Thereof CR were independent prognostic factors. In addition, fore, in young patients with low-grade NHL displaying a high number of infused MNC was associated with adverse prognostic features, new treatment modalities with poor DFS. HD patients: 30 (83%) were in CR after curative intention should be considered. 14-15 Regarding transplantation, with 25 maintaining CR at the end of Hodgkin's disease, high-dose chemotherapy with stem cell the study. Only one of the four patients transplanted support is becoming the preferred treatment for relapsing patients or for those who do not reach complete CR after polychemotherapy. Most of these patients are unlikely to
approximately one third of the patients may attain lasting patients had active disease, 13 sensitive and four were primary resistant. In the sensitive group, there were seven remissions. [17] [18] [19] In the present study we report on the outcome of 148 sensitive relapses, two untested relapses and four first PR. In the resistant group, all four patients were primary refraclymphoma patients uniformly conditioned with the BEAM scheme. In addition, a multivariate analysis including the tory. Sixteen patients were transplanted in second or subsequent CR. The remaining three patients were transplanted most relevant disease characteristics present both at diagnosis and at the time of transplant has been performed in in first CR: one with a slow CR (eight MOPP/ABV cycles were required) and two because they needed MOPP/ABV order to define the prognostic factors influencing survival and disease-free survival.
plus mini-BEAM therapy in order to achieve CR.
Patients and methods

Transplant procedure
All patients received the BEAM scheme as follows: BCNU Patient characteristics 300 mg/m 2 on day −6; etoposide 200 mg/m 2 on days −5 to One hundred and forty-eight patients with NHL (n = 112) −2 (total dose 800 mg/m 2 ), cytarabine 400 mg/m 2 on days or HD (n = 36) received high-dose chemotherapy with −5 to −2 (total dose 1600 mg/m 2 ) and melphalan 140 BEAM followed by autologous stem cell transplant mg/m 2 on day −1. Stem cells were infused on day 0. The (ASCT) at four centers in Spain. Patients were eligible for stem cell source was cryopreserved autologous bone mar-ASCT if they were р60 years and the lymphoma had row (BM) in 55 patients, peripheral blood hematopoietic relapsed or if they had failed to achieve remission after stem cells (PBSC) in 79 patients and both (BM + PBSC) induction curative chemotherapy. In addition, we transin 14 patients. PBSC were collected after chemotherapy planted some patients in first CR because they displayed plus G-or GM-CSF (11 patients) or G-CSF alone (80 two or more adverse prognostic factors (stages III and IV, patients). The median number of infused mononuclear cells performance status у2, extranodal disease, bulky tumour, (MNC) was 1.6 (range 0.3-4.9), 5.4 (0.5-16.7) and 4.8 high LDH/␤2 microglobulin (M) levels).
(1.6-10) for patients receiving BM, PBSC or BM + PBSC respectively. Non Hodgkin's lymphoma patients (NHL): According to the Working Formulation, patients with NHL were classified into three groups: low-grade (LGL:A, B, C), 28 Assessment of response to transplant (definitions) patients; intermediate-and high-grade large cell (IGL:D to H), 68 patients; and lymphoblastic high-grade (HGL) (I, J), One month before transplant, complete re-staging, evaluat-16 patients. Characteristics of NHL patients at diagnosis ing previously affected areas, was performed in every are listed in Table 1: 84% were at stages III and IV, and patient. Response to BEAM was evaluated 90 days after 40% had either high LDH or high ␤2M levels. Bulky distransplant. Complete remission (CR) was defined as comease was present in 57% of patients (Ͼ10 cm in 34% plete tumor disappearance, and partial remission (PR) as patients). Extranodal disease was observed in 64% of reduction of measurable disease by at least 50% without patients. According to the age-adjusted IPI, 75 patients the appearance of any new lesion. Progressive disease (PD) (67%) were in the intermediate-high group and 31 (28%) in was defined as an increase in measurable disease or the the high-risk group. Regarding disease status at transplant appearance of any new lesion. Stable disease (SD) was (Table 1) , 40% of patients had active disease and 19% were defined as unmodified disease after the transplant. Patients in 2nd or subsequent CR. In the group of patients with who died within 100 days after transplant were considered active disease (n = 45), 34 had sensitive disease (27 partial non-evaluable for response (NE). Early procedure-related remisions (PR) and seven sensitive disease) and 11 had mortality was defined as death within 100 days after highrefractory disease (three refractory relapses and eight pridose therapy. Toxic mortality was considered at any time mary refractory). The remaining 46 patients (41%) were if it was due to a recognized complication of the procedure. transplanted in first CR: 13 had LGL, 25 IGL and eight HGL. Eighteen went to transplant in first CR because they needed more than one anthracycline-containing regimen to Prognostic factors for survival achieve CR. The other 28 patients were transplanted due to the presence of two (seven patients) or more (19 cases)
Overall survival (OS) was calculated from day 0 until death adverse prognostic factors at diagnosis, or to a slow CR or date of last contact. Disease free-survival (DFS) was cal-(two patients that needed more than six ProMACE-MOPP culated from the day of the transplant to date of relapse, cycles to achieve CR).
death in remission or last follow-up while alive and in CR. Median follow-up was 30 months. The most relevant disease characteristics present at diagnosis and at the time of transplant were analyzed by univariate and multivariate Hodgkin's disease patients (HD): At diagnosis, 76% of patients were stages II-B to IVB and 45% had a tumor analysis for their possible roles as prognostic indicators for OS and DFS as previously described. 20 The variables evalumass bigger than 5 cm with half over 10 cm. Bone marrow infiltration was present in eight patients (22%) and 42% ated were at diagnosis and at transplant: age, sex, stage, performance status, LDH, ␤2M, ESR, Protein C, bulky disdisplayed extranodal disease. At transplant, 17 out of 36 ease, number of extranodal sites, histology and bone marResults row infiltration. Other characteristics analyzed were previous radiotherapy, status at transplant, source of stem cells, Transplant-related toxicity number of mononuclear cells infused, use of growth factors for transplant, and response after transplant. Age-adjusted Overall, the scheme was well tolerated. The main OMS toxicity was stomatitis, present in 84% of the patients international prognostic index (IPI) was included in the analysis of NHL patients. OS and DFS curves were plotted (grade III or IV in 30%) and diarrhoea which appeared in 69% of cases (grade 3 in 21 and grade 4 in two cases). according to the method of Kaplan and Meier, and compared statistically using the Mantel-Cox, Peto-Prentice and Hepatic toxicity occurred in 32% of the patients (2% grade 3; no grade 4 observed). Grade 1 renal toxicity was present Breslow tests. The cut-off point of each variable was selected by starting at its median value and then reducing from in 8% of cases. Eleven patients developed vesical toxicity (nine grade 1 and two grade 2). All except 19 patients had above and below until significance was eventually obtained. Variables considered for possible inclusion in the an infectious episode during the transplant. Four patients (2.7%), one HD and three NHL died of regression analysis were those for which there was some indication of a significant association in univariate analysis causes other than malignancy before day 100. Causes of death were: pulmonary fibrosis in one patient and infections (P Ͻ 0.1) or for which prior studies had suggested a possible association. The stepwise regression procedure was in the other three patients (Pseudomona septicemia and interstitial pneumonia). Four more patients died due to toxstopped when the P value for entering an additional factor was above 0.05. The model was tested both by expressing icity between days 120 and 210; causes of death were: acute Rhabdomyolysis due to Bacillus sp., septicemia and intervalues in a continuous way (continuous variables) and by grouping them into categories (dichotomous variables).
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stitial pneumonia in two cases. Therefore, the overall rate LGL = low-grade lymphoma; IGL = intermediate-and high-grade large cell; HGL = high-grade small cell; CR = complete remission; PR = partial response; SD = stable disease; PD = progressive disease; NE = not evaluable. * P = 0.002 (LGL vs IGL + HGL).
of transplant-related mortality was 5.4%. Within the group transplanted patients with active disease reached CR after of PBSC only one toxic death (pulmonary fibrosis) was the transplant (56%). Fifteen patients, four low-grade lymobserved (1.3%). Of the other patients who died, five had phoma, 11 intermediate-grade, relapsed between 106 and received BM alone and two had received BM + PBSC.
1261 days after transplant and three of them achieved subsequent CR. Interestingly, no patient with high-grade small cell lymphoma has relapsed. At the time of writing this Hematopoietic engraftment report, 83 patients (74%) are alive and 74 patients (66%) The median numbers of days to reach granulocytes are in continuous CR after the transplant, with a median 0.5 × 10 9 /l were 20 (range, 11-51), 12 (9-27) and 16 (13-follow-up of 30 months (3-70 months). 33) for patients receiving BM, PBSC or both, respectively.
The OS at 3 years was 68% (Table 2) and it was signifiPlatelets у20 × 10 9 /l were reached at 24 (10-250), 17 (10-cantly better for patients with low than high-intermediate 160) and 34 (12-157) days for the three groups described grade NHL (P = 0.002) (Figure 1 ). DFS at 3 years was above.
76% (Table 2 ). When we analyzed the DFS according to the adjusted-age IPI, the low-risk group (only six patients) Therapeutic results had a better DFS than the intermediate-and high-risk groups (75 vs 66 and 58% at 3 years, P = 0.05). DFS was Non-Hodgkin lymphoma: Table 2 shows the response of influenced by status of the disease at transplant: patients patients following transplant. Overall, at 3 months, 88 out transplanted in first CR or first PR showed a similar DFS, of the 112 NHL patients were in CR (81%) and 12 had that was significantly better than that of those transplanted progressed. The efficacy of transplant according to the previous status of the disease is shown in Table 3 . Half the in 2nd or subsequent CR or PR (86 vs 53% at 3 years, P Variables which influenced DFS in NHL patients in univariate analysis were disease status at transplant, ␤2M and a high number of MNC infused (у7 × 10 8 /kg). DFS at 3 years for patients who received less than 7 × 10 8 /kg was 81% compared to 32% for patients who received higher numbers of MNC (P = 0.0001). In multivariate analysis only the quantity of CMN infused influenced the DFS (P = 0.006). International prognostic index at diagnosis did not influence either OS or DFS.
Hodgkin's disease:
In the group of patients with HD (n = 36), 83% were in CR at 3 months after the transplant (Table  2 ). Eleven out of 17 patients (61%) transplanted with active disease achieved CR. Within this latter group, four patients had refractory disease and one reached CR (Table 3) 
Prognostic factors in Hodgkin's disease:
Six variables at = 0.0066) (Figure 2) . None of the patients transplanted with the time of transplant had a significant (P Ͻ 0.05) influence resistant disease was alive after 2 years. on the OS in HD patients: high LDH (Ͼ460) (P = 0.04), increased ESR (Ͼ40 mm) (P = 0.02), extranodal disease Prognostic factors in NHL: The univariate analysis for OS (P = 0.008), bone marrow infiltration (P = 0.03), high numshowed that 10 parameters had a significant adverse effect ber of MNC infused (Ͼ4 × 10 8 /kg), (0.01) and failure to on survival: three of them corresponded to characteristics achieve CR after transplant (0.0004). In the multivariate at diagnosis (histology, performance status and LDH) and analysis, only achieving CR after transplant (P = 0.000) another six were associated with either response to treatremained significant. Regarding DFS, only bone marrow ment (more than three regimens before the transplant and infiltration at diagnosis had prognostic influence on univarirefractory disease) or with other adverse prognosis factors ate analysis (0.02). at the time of transplant (bulky disease, extranodal disease, high LDH, poor performance status) ( Table 4 ). The final parameter with an adverse influence on OS was response Discussion to transplant: only 13% of patients who did not reach CR after the transplant were alive at 3 years compared to 77%
Non-Hodgkin's lymphoma of those who did (P Ͻ 0.0001). In multivariate analysis only response to the transplant, histology (low vs intermedi-
The role of autologous transplant in the treatment of NHL patients remains controversial. It has been shown to be a ate and high grade), bulky disease and poor performance status remained independent variables. potentially curative treatment for a subset of patients with NHL who relapse from primary therapy or who are in partial remission with disease which is still sensitive.
21-25
This has recently been confirmed by Philip et al 9 in a randomized study showing an OS at 5 years of 53% for transplanted patients with intermediate-and high-grade lymphoma as compared to 32% in the chemotherapy group (P = 0.038). The efficacy of transplant as consolidation therapy for high-risk patients in first CR after first-line treatment has also been suggested by several groups 10, [26] [27] [28] and confirmed by Haioun et al 10 in a randomized trial. The present study supports the efficacy of ASCT as consolidation therapy for NHL patients with adverse prognostic factors (OS and DFS of 76 and 86%, respectively). Moreover, in contrast with the findings of Prince et al, 29 no differences were observed between patients transplanted in first CR and those transplanted in first PR. Both groups displayed a significantly better outcome than those transplanted after relapsing, although the outcome of the patients is still relatively good (DFS of 55% at 3 years), this con- groups, 25, 30, 31 results in refractory patients are very poor: ical techniques (data not shown). Although randomized studies and longer follow-up should confirm the efficacy of only 8% of our patients were alive at 225 days and none survived at 3 years. the transplant in this set of patients in terms of overall survival, there are other reasons for considering early When we analyze the results separately according to histology, in the group of patients with intermediate-and hightransplant in young LGL patients with poor prognosis: one reason is to avoid repetitive chemotherapy which could grade large cell lymphoma, the OS and DFS were good (56 and 71%, respectively), especially if we consider that this increase the risk of MDS or secondary tumors; another important reason is the excellent quality of life for patients cohort of patients displayed very poor prognostic features (90% were in the intermediate-and high-risk group accordtransplanted in CR.
Although toxicity with PBSC is very low (5.4% in our ing to the IPI). Interestingly, none of the patients with highgrade lymphoma who were in CR 3 months after transplant series), due to the cost of the procedure, criteria for predicting response would be a valuable tool in clinical have relapsed and all are probably cured. In conclusion, according to our experience and due to the poor results decision making, thereby avoiding the emotional and financial burden of an ineffective treatment. In our multivariobtained with standard therapy with less than 50% of patients cured, 32 there is a clear indication for transplanting ate analysis, the only independent prognostic factor influencing DFS was the number of MNC infused. We do not intermediate-and high-grade NHL patients with adverse prognostic factors in first CR.
have a clear explanation for the adverse influence of infusing high numbers of MNC. In fact, this parameter was indeThe promising results achieved with ASCT in high and intermediate NHL have generated interest in the possible pendent of the presence or absence of BM infiltration. Therefore, a possible explanation is that patients receiving role of such a strategy in LGL. However, the number of studies in this latter subgroup of NHL patients is still a higher number of MNC display a greater risk of tumor contamination. In line with this possibility, Gribben et al 39 scanty. [33] [34] [35] [36] [37] [38] The OS at 10 years with conventional chemotherapy in LGL patients with poor prognostic factors is and Sharp et al 40 have shown that infusion of contaminated products assessed by PCR or cell cultures, correlates with below 50%. 13 We have transplanted 28 LGL patients resulting in an OS of 88%, with 20 patients in CCR, DFS. 39, 40 The present observation would raise concern about the importance of careful controls of products to be assessed not only by morphology but also by immunolog- 
